Zacks Investment Research Lowers CHF Solutions (NASDAQ:CHFS) to Sell

Zacks Investment Research cut shares of CHF Solutions (NASDAQ:CHFS) from a hold rating to a sell rating in a research report sent to investors on Monday morning, Zacks.com reports.

According to Zacks, “CHF Solutions, Inc. is a medical device company which focused on commercializing the Aquadex FlexFlow (R) System. Its commercial product Aquadex system, is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. CHF Solutions Inc., formerly known as Sunshine Heart Inc., is headquartered in Minneapolis. “

Separately, ValuEngine cut Zosano Pharma from a buy rating to a hold rating in a report on Wednesday, May 1st.

CHFS traded down $0.09 during trading hours on Monday, reaching $2.85. 104,841 shares of the company’s stock traded hands, compared to its average volume of 140,521. The company’s 50-day moving average price is $3.11. CHF Solutions has a 52-week low of $2.57 and a 52-week high of $26.60. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.86 and a quick ratio of 5.12. The firm has a market capitalization of $6.57 million, a price-to-earnings ratio of -0.07 and a beta of 2.35.

CHF Solutions (NASDAQ:CHFS) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($11.47) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.42) by ($10.05). CHF Solutions had a negative net margin of 336.26% and a negative return on equity of 188.60%. The business had revenue of $1.22 million for the quarter. Sell-side analysts forecast that CHF Solutions will post -5.53 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of CHFS. Vanguard Group Inc purchased a new stake in shares of CHF Solutions in the 3rd quarter worth $39,000. Virtu Financial LLC bought a new position in shares of CHF Solutions in the 1st quarter worth $58,000. Finally, Perkins Capital Management Inc. bought a new position in shares of CHF Solutions in the 1st quarter worth $470,000. Institutional investors own 10.17% of the company’s stock.

About CHF Solutions

CHF Solutions, Inc, a medical device company, focuses on the provision of solutions for patients suffering from fluid overload. The company's commercial product is the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.

Read More: Blockchain

Get a free copy of the Zacks research report on CHF Solutions (CHFS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.